Pulmonary Artery Aneurysm
Pulmonary artery aneurysm is an uncommon yet significant contributor to the spectrum of pulmonary vascular disorders. At Protheragen, we are devoted to redefining the landscape of rare cardiovascular disease studies. With expertise in a full range of drug discovery and development services, we provide one-stop solutions for problems such as pulmonary artery aneurysm. Our comprehensive solutions span diagnostic developments, breakthrough therapeutics, customized disease models, and carefully designed preclinical experiments.
Introduction to Pulmonary Artery Aneurysm
Pulmonary artery aneurysm is an unusual malformation of the pulmonary vasculature. Varies between studies, with most autopsy studies reporting an incidence of 1 per 14,000. These aneurysms may occur as a consequence of infection, malignancy, congenital heart disease, or vasculitis. They are associated with potentially life-threatening complications, including massive hemoptysis from rupture, acute coronary syndrome due to coronary artery compression, and pulmonary artery dissection.
Fig.1 Chest CT angiography that showed a pulmonary artery aneurysm. (Gupta, M., et al., 2020)Pathogenesis of Pulmonary Artery Aneurysm
The development of pulmonary artery aneurysm is complicated and frequently multifactorial, with an interplay of factors that result in the dilatation and weakening of the pulmonary arterial wall. It may be divided into congenital and acquired etiology. Mostly abnormal hemodynamics (e.g., too high pressure and flow from congenital heart defects like PDA or VSD or chronic pulmonary hypertension), intrinsic weakness of the arterial wall (connective tissue disorders such as Marfan or Ehlers-Danlos syndromes, idiopathic degeneration), and direct damage due to inflammation or infection.
Fig.2 Genes associated with thoracic aortic aneurysms. (Nuche, J., et al., 2020)Therapeutics Development for Pulmonary Artery Aneurysm
| Drug Name | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|
| Glucocorticoids | Strong anti-inflammatory and immunosuppressive agents aim to quell the inflammation in the walls of the blood vessels that causes an aneurysm to form or grow. | Glucocorticoid Receptor | Approved |
| Cyclophosphamide | It assists in obtaining higher and more persistent immunosuppression to avoid aneurysm growth and rupture. | DNA | Approved |
| Infliximab | Biologic agents that specifically target tumor necrosis factor-alpha (TNF-α). They reduce inflammation by tamping down TNF-α. | TNF-α | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
Important features of our comprehensive service portfolio are customized for rare drug development in rare cardiovascular diseases. In diagnostics, we use the latest technology to discover new biomarkers and produce accurate diagnostic assays. For therapeutics, we provide one-stop services from lead optimization and target validation to preclinical efficacy studies. One of our core services is disease model generation, where we generate and validate in vitro and in vivo models to drive drug efficacy.
Therapeutic Development Services
Diverse Platforms
Animal Model Development for Pulmonary Artery Aneurysm
Animal models of rare cardiovascular diseases, such as pulmonary artery aneurysm, are essential for understanding disease pathogenesis, discovering therapeutic targets, and testing new interventions. Our company offers you a wide variety of proven, reliable preclinical research animal models. You can rely on our expert team for the specialized assistance you need in viable preclinical research models and for offering you the quality research tools for your pioneering research into pulmonary artery aneurysm.
These models rely on chemical agents or environmental stimuli to induce conditions that lead to pulmonary artery aneurysm.
- Hypoxia/SU5416 induced model
- Other models
These models involve modifying specific genes to induce conditions that predispose to or directly cause pulmonary artery aneurysm, often mimicking human genetic disorders.
- Fbn1C1041G/+ model
- Other models
Protheragen offers a complete range of drug development services, which range from accurate pharmacokinetic studies and thorough drug safety assessments, all tailored with care for your requirements. Use our experience to support you in solving bottlenecks, minimizing risks, and fully exploiting the potential of your candidate therapeutics. Get in touch today and find out how our combined services can save you time and speed time to market.
References
- Nuche, Jorge et al. "Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta." International journal of molecular sciences 21.7 (2020): 2509
- Gupta, Mridul et al. "Pulmonary artery aneurysm: a review." Pulmonary circulation 10.1 (2020): 2045894020908780.
For research use only, not for clinical use.